LIGAND PHARMACEUTICALS INCORPORATED Equity Securities, FV-NI, Gain (Loss)
LIGAND PHARMACEUTICALS INCORPORATED (LGND) reported Equity Securities, FV-NI, Gain (Loss) of $50.19 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiGainLoss · last filed 2019-02-28
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, gain (loss) for fiscal 2018 was $50.19M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, gain (loss) for fiscal 2017 was -$2.05M.
- LIGAND PHARMACEUTICALS INCORPORATED equity securities, fv-ni, gain (loss) for fiscal 2016 was -$23.13M.
| Period end | Equity Securities, FV-NI, Gain (Loss) 12 month |
|---|---|
| 2018-12-31 | $50.19M 10-K · filed 2019-02-28 |
| 2017-12-31 | -$2.05M 10-K · filed 2019-02-28 |
| 2016-12-31 | -$23.13M 10-K · filed 2019-02-28 |